BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25281405)

  • 1. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.
    Sweet K; Al Ali NH; Dalia SM; Komrokji RS; Crescentini RM; Tinsley S; Lancet JE; Papenhausen PR; Zhang L; Pinilla-Ibarz J
    Int J Hematol; 2014 Dec; 100(6):567-74. PubMed ID: 25281405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
    Patkar N; Ghodke K; Joshi S; Chaudhary S; Mascerhenas R; Dusseja S; Mahadik S; Gaware S; Tembhare P; Gujral S; Kabre S; Kadam-Amare P; Jain H; Dangi U; Bagal B; Khattry N; Sengar M; Arora B; Narula G; Banavali S; Menon H; Subramanian PG
    Leuk Lymphoma; 2016 Nov; 57(11):2653-60. PubMed ID: 26999421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
    Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
    Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
    Savasoglu K; Payzin KB; Ozdemirkiran F; Subasioglu A; Yilmaz AF
    Leuk Lymphoma; 2017 Aug; 58(8):1958-1962. PubMed ID: 27924671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
    Branford S; Rudzki Z; Walsh S; Parkinson I; Grigg A; Szer J; Taylor K; Herrmann R; Seymour JF; Arthur C; Joske D; Lynch K; Hughes T
    Blood; 2003 Jul; 102(1):276-83. PubMed ID: 12623848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia.
    Yoo HL; Kim SH; Choi SY; Lee SE; Kim DW
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):406-412.e1. PubMed ID: 30928650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
    Kagita S; Uppalapati S; Jiwatani S; Linga VG; Gundeti S; Nagesh N; Digumarti R
    Tumour Biol; 2014 Jul; 35(7):7187-93. PubMed ID: 24763825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
    Vaidya S; Vundinti BR; Shanmukhaiah C; Chakrabarti P; Ghosh K
    PLoS One; 2015; 10(1):e0114828. PubMed ID: 25629972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in ABL kinase domain are associated with inferior progression-free survival.
    Sharma P; Mohanty S; Kochupillai V; Kumar L
    Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
    Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
    Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
    Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
    Müller MC; Cortes JE; Kim DW; Druker BJ; Erben P; Pasquini R; Branford S; Hughes TP; Radich JP; Ploughman L; Mukhopadhyay J; Hochhaus A
    Blood; 2009 Dec; 114(24):4944-53. PubMed ID: 19779040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.